( SPIRIT FIRST Demonstrates Continued Saf...)Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials,Health

BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Three-year data from the SPIRIT FIRST trial demonstrated no additional Major Adverse Cardiac Events (MACE), and no late stent thrombosis in patients treated with either Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent System or its MULTI-LINK VISION(R) metallic coronary stent. Additionally, data presented from a meta- (combined) analysis of SPIRIT II and SPIRIT III trials at nine months reaffirmed the superiority of Abbott's XIENCE V compared to the TAXUS(R) paclitaxel-eluting coronary stent system in a variety of measures.

These data were presented today at the EuroPCR meeting in Barcelona.

"The SPIRIT FIRST results support the long-term safety of the XIENCE V system, with no additional MACE or late stent thrombosis, by both protocol and ARC definitions, out to three years," said Gregg W. Stone, M.D., of Medical Center and the Cardiovascular Research Foundation, New York, and an investigator in the SPIRIT trials. "In addition, a meta-analysis of the SPIRIT II and III data again demonstrated the superiority of the XIENCE V system to the TAXUS system in important measures that matter to patients including renarrowing of a treated vessel and major adverse cardiac events."

A meta-analysis of approximately 1,300 patients from the SPIRIT II and SPIRIT III clinical trials conducted by the Cardiovascular Research Foundation indicated that the XIENCE V system demonstrated superiority over the TAXUS stent in angiographic (imaging) and clinical endpoints, with an excellent safety profile.

Specifically, data from the meta-analysis demonstrated that the XIENCE V Everolimus Eluting Coronary Stent System was superior to the TAXUS stent in:

    -- Reducing the occurrence of major 
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work
Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First
Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. New Analysis of Data Shows Treatment With Abbotts Humira
(Adalimumab) Significantly Reduced Disease-Related Hospitalization
for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results
in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the
Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and
Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First
Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to
Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the

American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis